Ascentage Pharma Group International (AAPG) News Today $47.90 +0.21 (+0.44%) As of 08/22/2025 03:32 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock AAPG Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Monashee Investment Management LLC Buys New Shares in Ascentage Pharma Group International - Unsponsored ADR $AAPGAugust 23 at 8:31 AM | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Up 1.7% - Here's What HappenedAugust 23 at 5:53 AM | marketbeat.comASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesAugust 21 at 8:19 AM | finanznachrichten.deAscentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesAugust 20, 2025 | globenewswire.comAscentage Pharma’s Lisaftoclax Phase III Trial for HR-MDS Cleared by FDA and EMAAugust 18, 2025 | msn.comAscentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMAAugust 17, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month High - Should You Buy?August 17, 2025 | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Here's WhyAugust 16, 2025 | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's What HappenedAugust 12, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)August 12, 2025 | theglobeandmail.comAscentage Pharma to Announce 2025 Interim Results and Corporate UpdateAugust 12, 2025 | theglobeandmail.comAscentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025August 7, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Here's What HappenedAugust 6, 2025 | marketbeat.comAscentage Pharma to Participate in Evercore China Biotech SummitAugust 1, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - What's Next?July 28, 2025 | marketbeat.comAAPG Ascentage Pharma Group International - Seeking AlphaJuly 25, 2025 | seekingalpha.comAscentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025July 24, 2025 | finance.yahoo.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Time to Sell?July 22, 2025 | marketbeat.comAscentage Pharma Raises $192.3M Through Oversubscribed Offshore Share PlacementJuly 21, 2025 | msn.comAscentage Pharma Announces Closing of Placement Shares in Top-Up PlacementJuly 17, 2025 | globenewswire.comAscentage Pharma Group International - Unsponsored ADR's (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rdJuly 16, 2025 | marketbeat.comAscentage Pharma’s Novel Cancer Drug Approved in ChinaJuly 15, 2025 | finance.yahoo.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Should You Buy?July 15, 2025 | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Should You Sell?July 14, 2025 | marketbeat.comAscentage Pharma Announces Pricing of Top-Up PlacementJuly 14, 2025 | globenewswire.comAscentage Pharma Announces Proposed Top-Up PlacementJuly 14, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Down 4.4% - Should You Sell?July 11, 2025 | marketbeat.comASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLLJuly 10, 2025 | finanznachrichten.deAscentage Pharma Announces NMPA Approval for Blood Cancer DrugJuly 10, 2025 | finance.yahoo.comAscentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLLJuly 10, 2025 | globenewswire.comAscentage Pharma Strengthens Leadership with Key AppointmentsJuly 10, 2025 | theglobeandmail.comASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate ...July 9, 2025 | finanznachrichten.deAscentage Pharma appoints Veet Misra as CFOJuly 8, 2025 | msn.comAscentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and FinanceJuly 7, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Hits New 1-Year High - Should You Buy?June 24, 2025 | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Reaches New 1-Year High - Here's What HappenedJune 16, 2025 | marketbeat.comEHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALLJune 15, 2025 | globenewswire.comThirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual CongressJune 9, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month High - Here's What HappenedJune 9, 2025 | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Reaches New 12-Month High - Here's WhyJune 3, 2025 | marketbeat.comLive from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral ReportJune 2, 2025 | globenewswire.comLive from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid TumorsJune 2, 2025 | globenewswire.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Down 6.2% - Here's What HappenedMay 30, 2025 | marketbeat.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Up 5.9% - Time to Buy?May 30, 2025 | marketbeat.comAscentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025May 22, 2025 | globenewswire.comIs Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?May 12, 2025 | msn.comAscentage Pharma Group International ADRApril 29, 2025 | morningstar.comMAscentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with LisaftoclaxApril 28, 2025 | globenewswire.comHigh Growth Tech Stocks in Asia to Watch This April 2025April 25, 2025 | finance.yahoo.comAscentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Time to Buy?April 24, 2025 | marketbeat.com Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address AAPG Media Mentions By Week AAPG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AAPG News Sentiment▼0.450.69▲Average Medical News Sentiment AAPG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AAPG Articles This Week▼72▲AAPG Articles Average Week Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GMAB News VTRS News RDY News ASND News QGEN News MRNA News BBIO News ELAN News VRNA News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AAPG) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access